Policy
Jim O’Neill was deputy secretary at the Department of Health and Human Services and also acting director of the CDC after the abrupt ouster of Susan Monarez in August 2025.
FEATURED STORIES
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Heading into fall, with the COVID-19 pandemic surging again and researchers tracking new variants, there’s plenty of news. Here’s a look.
The Biden administration announced plans for a new biopreparedness initiative that is part of the ongoing Building Back Better plan.
Concerns about Mu and Lambda are growing, but data suggests that Delta is still the biggest problem. The U.S. is also struggling with infections this year. Here’s the latest news.
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.
Lilly’s most recent legal woes come from a proposed class-action lawsuit filed on Wednesday, accusing the company of age bias.
Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.
The Sacklers did not admit to any wrongdoing and have never been charged directly for the issue. Still, Purdue Pharma has pleaded guilty twice in its erroneous marketing efforts for OxyContin.
Multiple reports suggest an exodus of BIO team members over price control issues. BIO reorganized its leadership structure to provide what was expected to be “long-term stability for the organization.”
New data is coming out every day about COVID-19 and the body’s response to vaccines. Here’s a look at some of the top stories.